• About us
• Contact

Advertisement

Organisation › Details

Merck China Biologics Testing Center (Shanghai)

In September 2022 Merck opened a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center. The 5,000 square meter center is the first of its kind for Merck in China. The VC laboratory allows customers to locally conduct viral clearance studies from pre-clinical development to commercialization and will meet the double-digit demand for VC testing services in China.1 The VC laboratory will add around 120 jobs by 2023. The first building phase of the center adds laboratory capacity for viral clearance studies, one of the most critical steps in drug development. These studies are key to supporting the Investigational New Drug (IND) and Biologics License Application (BLA) filing milestones, which are required by regulatory agencies around the world to complete clinical trials and move to commercial manufacturing. The second phase of the center’s facilities will open in late 2023 and will offer cell line characterization and lot release testing services. The facility in Shanghai joins Merck’s global viral clearance suites network with sites in Singapore; Stirling, UK; and Rockville, Maryland, USA, and shares the same global expertise, standards, and operating systems. *

 

	Start	2022-09-21 start
	Group	Merck (DE) (Group)
	Industry	BioReliance® End-to-End Solutions
	Industry 2	drug development services
	Region	Shanghai
	Country	China
	City	n. a. Shanghai
		Address record changed: 2022-09-25
Basic data	Employees	n. a.
		* Document for »About Section«: Merck KGaA. (9/21/22). "Press Release: Merck Opens New € 29 Million Biologics Testing Center in Shanghai". Shanghai.
		Record changed: 2024-09-22

Advertisement

More documents for Merck (DE) (Group)

• [1] Merck KGaA. (4/25/24). "Press Release: Merck Invests More Than € 300 Million in New Life Science Research Center in Germany". Darmstadt....
• [2] Merck KGaA. (9/12/23). "Press Release: Merck Appoints Axel Löber as Head of Global Communications and Stakeholder Engagement". Darmstadt....
• [3] Endress+Hauser AG. (1/27/23). "Press Release: Change at the Top of Analytik Jena. Ulrich Krauss Charts New Course; Oliver Klaeffling Set to Become Managing Director"....
• [4] Merck KGaA. (11/21622). "Press Release: Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity". Darmstadt....
• [5] Merck KGaA. (9/21/22). "Press Release: Merck Opens New € 29 Million Biologics Testing Center in Shanghai". Shanghai....
• [6] Merck KGaA. (4/29/22). "Press Release: Merck Invests Approximately € 100 Million to Accelerate Single-Use Manufacturing in China". Darmstadt....
• [7] Merck KGaA. (2/7/22). "Press Release: Merck Announces Organizational Transformation of Life Science Business Sector to Strengthen CDMO Offering and Accelerate Future Growth". Darmstadt....
• [8] Merck KGaA. (9/22/21). "Press Release: Sabia Schwarzer Appointed Head of Group Communications, Brand and Corporate Affairs at Merck". Darmstadt....
• [9] Merck KGaA. (10/8/20). "Press Release: Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant". Darmstadt....
• [10] Merck KGaA. (9/28/20). "Press Release: Stefan Oschmann to Hand Over Chair of Executive Board to Belén Garijo in 2021". Darmstadt....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.